HMGB1 and neoplasm: Furthermore, the immune checkpoint receptor T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) on tumor-associated DCs was able to abrogate therapy-induced immunogenicity of cell death by interacting with HMGB1.